Results of a clinical trial with bromperidol C-C 2489/21.
A controlled clinical study--phase III--with bromperidol was conducted on 30 male patients with a diagnosis of schizophrenia of different subtypes, realized by psychiatric assessments and by laboratory measures over an eight-week investigational period. A global improvement (from very much up to moderately) was achieved in 76% of the patients; two patients dropped out. The optimal dosage of bromperidol seemed to lie between 4 and 6 mg/day. The adverse effects were confined to moderate extrapyramidal symptoms in the extent of a higher dosage. Bromperidol appears to be a potent longacting neuroleptic drug without essential psychomotor damping, anxiolytic and hypnosedating properties, but with a strong antipsychotic potential against the basic schizophrenic disintegration. It is mainly indicated in paranoia, depressive-paranoia and simple forms of schizophrenia.
D000293:Adolescent; D000328:Adult; D017109:Akathisia, Drug-Induced; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*
D006220:Haloperidol